INmune Bio Inc
Research INmune Bio Inc (INMB) on Bullrun: market cap USD 43.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINMB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 43.07M
- Financial periodFY2025
- RevenueUSD 50.00K
- Revenue growth257.1%
- Net income-USD 46.00M
- Free cash flow-USD 23.62M
Valuation Snapshot
latest market cap is USD 43.07M.
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.
Frequently asked questions
What is INmune Bio Inc's market cap?
INmune Bio Inc's market capitalization is USD 43.07M.
What does INmune Bio Inc do?
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.